Phase II study of VDT (velcade, Doxil and thalidomide) [bortezomib + doxorubicin liposomal + thalidomide] as frontline therapy for patients with previously untreated multiple myeloma (MM).

Trial Profile

Phase II study of VDT (velcade, Doxil and thalidomide) [bortezomib + doxorubicin liposomal + thalidomide] as frontline therapy for patients with previously untreated multiple myeloma (MM).

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Bortezomib (Primary) ; Doxorubicin liposomal (Primary) ; Thalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 11 Dec 2007 Results will be presented at the 49th annual meeting of the American Society of Hematology.
    • 07 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top